Dr. Francesca Capotosti is the Group Leader for in vivo pharmacology and non-clinical safety at AC Immune, where she is responsible for leading in vivo pharmacology, ADME, DMPK, and toxicology activities for the Company’s small molecule, vaccine, and monoclonal antibody candidates. She also serves as Global Project Leader for the alpha-synuclein PET program. Previously, she served as Research Scientist and then Team Leader, working primarily on small molecules targeting Tau as therapeutic and diagnostic agents. Before joining AC Immune in 2013, Dr Capotosti worked as postdoctoral fellow in the Bioengineer Department of the École Polytechnique Fédérale de Lausanne (EPFL), focusing on new therapeutic approaches for immuno-oncology. Dr Capotosti holds a PhD in life science from the University of Lausanne, work for which she obtained the Young Investigator Award, and a Master Degree in pharmaceutical chemistry from the University of Pisa, Italy.

Autumn is a fourth-year student in the BScN program at Nipissing University. Before pursuing a career as a registered nurse, Autumn graduated with an Honours Bachelor degree in Kinesiology from the University of Western Ontario in 2016 and completed two years of a Master's program before deciding to change her trajectory. Over the past four years, Autumn has found her passion in caring for others in need and has an ongoing interest in continuing education within the healthcare field. Autumn has been involved in several research projects, presentations, and publications in the areas of endocrinology, drug target development, epigenomics, and Parkinson's disease and hopes to integrate her learning into her future practice.

Greg Carter is a Professor and the Bernard and Lusia Milch Chair at the Jackson Laboratory, where his research group combines genetic, genomic, imaging, and other data resources to understand the causes and progression of Alzheimer’s disease. He is Head of Bioinformatics for the IU/JAX/Pitt Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease (MODEL-AD) and the Emory/Sage/SGC Target Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) Centers. His lab is focused on developing computational and experimental strategies to optimize the use of model systems in understanding Alzheimer’s disease and related-dementias. Their work involves the creation and study of new animal models to dissect the genetics, genomics, and neuropathology of late-onset Alzheimer’s, and the integration of data across multiple platforms to prioritize targets and hypotheses for novel therapeutics.

Veronica Castelnovo is a neuropsychologist. Since October 2018 she is PhD candidate in the International PhD program in Molecular Medicine at the Vita-Salute San Raffaele University of Milan (Italy). She is involved in research projects on the frontotemporal lobar degeneration spectrum and on motor neuron diseases, aimed at monitoring the progression of the disease both from a cognitive/ behavioral point of view and from the brain magnetic resonance imaging using advanced analysis techniques.